Fenwick represented Aceragen on the deal, Morgan Lewis advised Idera Pharmaceuticals. Aceragen, a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here